A randomised, double-blind, dose-comparison study of weekly interferon ß-1a in relapsing MS (2002)
Clanet,M., Radue,E. W., Kappos,Ludwig, Hartung,Hans Peter, Hohlfeld,Reinhard, Sandberg-Wollheim,M., ...
Interferon beta-1a (IFNbeta-1a; Avonex) is effective for the treatment of relapsing MS; however, the optimal dose of IFNbeta-1a is not known. OBJECTIVE: To determine whether IFNbeta-1a 60 micro g IM...
A randomised, double-blind, dose-comparison study of weekly interferon ß-1a in relapsing MS (2002)
Clanet, M., Radue, E. W., Kappos, Ludwig, Hartung, Hans Peter, Hohlfeld, Reinhard, Sandberg-Wollheim, M., ...
Interferon beta-1a (IFNbeta-1a; Avonex) is effective for the treatment of relapsing MS; however, the optimal dose of IFNbeta-1a is not known. OBJECTIVE: To determine whether IFNbeta-1a 60 micro g IM...
Utilité de l'inflammation en certains cas de maladies externes. (1800)
Montpellier theses.
A Second-Generation Genomic Screen for Multiple Sclerosis
Kenealy, S. J., Bradford, Y., Schnetz-Boutaud, N., Haines, J. L., Rimmler, J. B., ...
Multiple sclerosis (MS) is a debilitating neuroimmunological and neurodegenerative disorder. Despite substantial evidence for polygenic inheritance of the disease, the major histocompatibility...
Mutations within the Programmed Cell Death 10 Gene Cause Cerebral Cavernous Malformations
Bergametti, F., Denier, C., Labauge, P., Arnoult, M., Boetto, S., Clanet, M., ...
Cerebral cavernous malformations (CCMs) are hamartomatous vascular malformations characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. They cause seizures and...
Edan, G, Miller, D, Clanet, M, Confavreux, C, Lyon-Caen, O, Lubetzki, C, ...
OBJECTIVE: To evaluate the efficiency of mitoxantrone in multiple sclerosis. METHODS: Forty two patients with confirmed multiple sclerosis, selected as having a very active disease on clinical and...
Long-term treatment of Parkinson's disease with bromocriptine.
Rascol, A, Guiraud, B, Montastruc, J L, David, J, Clanet, M
BRomocriptine (15-75 mg per day) alone or with L-dopa was studied during five to 29 months on 44 patients with Parkinson's disease. Used as sole therapeutic agent, it was found excellent in 12...
Square wave jerks in parkinsonian syndromes.
Rascol, O, Sabatini, U, Simonetta-Moreau, M, Montastruc, J L, Rascol, A, Clanet, M
The frequency of square wave jerks (SWJ) was compared in eight patients with progressive supranuclear palsy (PSP), 25 patients with multiple system atrophy or Parkinson's disease plus (MSA/PP), 85...